```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:37:14 ON 09 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 9 Jan 2008  VOL 148 ISS 2
FILE LAST UPDATED: 8 Jan 2008  (20080108/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitstr l18 tot
```

L18 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1348899 HCAPLUS
TI Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats
AU Enomoto, Takeshi; Ishibashi, Tadashi; Tokuda, Kumiko; Ishiyama, Takeo; Toma, Satoko; Ito, Akira
CS Discovery Pharmacology II, Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., 3-1-98, Kasugade Naka, Konohana-ku, Osaka, 554-0022, Japan
SO Behavioural Brain Research (2008), 186(2), 197-207
CODEN: BBREDI; ISSN: 0166-4328
PB Elsevier B.V.
DT Journal
LA English
AB We have previously shown that lurasidone, a novel atypical antipsychotic, potently reverses learning impairment induced by the N-methyl--aspartate receptor antagonist MK-801 in the rat passive avoidance test. However, the effects of lurasidone in other learning and memory tasks remain to be investigated. We investigated the effects of lurasidone and other marketed antipsychotics (risperidone, clozapine, aripiprazole, and haloperidol) on MK-801-induced impairment of learning and memory in the Morris water maze (MWM) and radial-arm maze (RAM) tests in rats. Learning and memory impairment in the MWM test, as measured by escape latency, escape distance, and diving behavior, and in the RAM test, as measured by reference and working memory errors, was induced by MK-801 (i.p.) at doses of 0.15 and 0.2 mg/kg, resp. In the MWM test, lurasidone (1 and 3 mg/kg p.o.) potently reversed MK-801-induced learning impairment. In the RAM test, lurasidone (1 and 3 mg/kg p.o.) potently reversed MK-801-induced reference memory impairment and moderately but not significantly attenuated MK-801-induced working memory impairment. Risperidone (0.3 and 1 mg/kg p.o.), clozapine (3 and 10 mg/kg p.o.), aripiprazole (0.3 and 1 mg/kg p.o.), and haloperidol (0.3 and 1 mg/kg p.o.) did not reverse MK-801-induced impairment of learning and memory in both tasks. Lurasidone, but not the other antipsychotics tested in this study, reverses MK-801-induced impairment of learning and memory in both the MWM test and the RAM test. These results suggest that lurasidone would be more effective in treating schizophrenics with cognitive dysfunction than current antipsychotics.

L18 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1076353 HCAPLUS
DN 147:440137
TI Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test
AU Ishiyama, Takeo; Tokuda, Kumiko; Ishibashi, Tadashi; Ito, Akira; Toma, Satoko; Ohno, Yukihiro
CS Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co. Ltd., Suita, Osaka, 564-0053, Japan
SO European Journal of Pharmacology (2007), 572(2-3), 160-170
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier B.V.
DT Journal
LA English
AB Lurasidone (SM-13496) is a novel atypical antipsychotic with high affinities to dopamine D2, serotonin 5-HT7, 5-HT2A, 5-HT1A receptors and α2C adrenoceptor. In this study, the effects of lurasidone on the rat passive-avoidance response and its impairment by the N-methyl--aspartate (NMDA) receptor antagonist MK-801 (dizocilpine) were evaluated and compared with those of other antipsychotics. The passive-avoidance response was examined by measuring the step-through latency, 1 day after the animals received foot-shock training. When given before the training session, lurasidone did not affect the passive-avoidance response at any dose tested (1-30 mg/kg, p.o.). All the other atypical antipsychotics examined (i.e., risperidone, olanzapine, quetiapine, clozapine and aripiprazole), however, significantly reduced the step-through latency at relatively high doses. A pre-training administration of lurasidone significantly and dose-dependently reversed the MK-801-induced impairment of the passive-avoidance response. At doses lower than those that affected the passive-avoidance response, risperidone, quetiapine, and clozapine partially reduced the MK-801-induced impairment, whereas haloperidol, olanzapine, and aripiprazole were inactive. In addition, the post-training administration of lurasidone was as effective in countering the MK-801 effect as the pre-training administration, suggesting that lurasidone worked, at least in part, by restoring the memory consolidation process disrupted by MK-801. These results suggest that lurasidone is superior to other antipsychotics in improving the MK-801-induced memory impairment and may be clin. useful for treating cognitive impairments in schizophrenia.
IT 367514-87-2, Lurasidone
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SM-13496; lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in rat passive-avoidance test)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 367514-88-3, SM-13496
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in rat passive-avoidance test)
RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1337840 HCAPLUS
DN 146:68724
TI Pharmaceutical solutions containing lurasidone
IN Otoda, Kazuya; Nakamura, Mayumi; Ariyama, Teruko; Nakagawa, Takashi
PA Dainippon Sumitomo Pharma Co., Ltd., Japan
SO PCT Int. Appl., 21pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2006134864	A1	20061221	WO 2006-JP311739	20060612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI JP 2005-172725	A	20050613		

AB A solution-type preparation comprises lurasidone or its acid addition salts, preferably hydrochloride salt, as an active ingredient and at least one substance selected from benzyl alc., N,N-dimethylacetamide, lactic acid and propylene glycol. The solns. comprise high concentration of lurasidone for the treatment of mental disorders.
IT 367514-87-2, Lurasidone 367514-88-3, Lurasidone hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical solns. containing lurasidone)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1252571 HCAPLUS
DN 146:13212
TI Oral pharmaceutical compositions of lurasidone
IN Fujihara, Kazuyuki
PA Dainippon Sumitomo Pharma Co., Ltd., Japan
SO PCT Int. Appl., 42pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2006126681	A1	20061130	WO 2006-JP310571	20060526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU2006250340	A1	20061130	2006AU-0250340	20060526
PRAI 2005JP-0153508	A	20050526		
WO 2006-JP310571	W	20060526		

AB A preparation for oral administration comprises a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxy imide hydrochloride (lurasidone hydrochloride) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, where the preparation exhibits an invariant level of elution behavior even when the content of its active ingredient is varied. For example, tablets were formulated containing lurasidone 80, mannitol 144, pregelatinized starch 80, croscarmellose sodium 4, hydroxypropyl Me cellulose 8, and Mg stearate 4 mg per tablet and film coated with a composition containing hydroxypropyl Me cellulose, titania, polyethylene glycol, and carnauba wax.
IT 367514-87-2, Lurasidone 367514-88-3, Lurasidone hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. of lurasidone with improved dissoln. profile)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 367514-88-3 HCAPLUS

L18 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:627401 HCAPLUS
DN 145:83396
TI Preparation of imides as intermediates for psychotropic agents
IN Ae, Nobuyuki; Bando, Hisashi
PA Sumitomo Chemical Co., Ltd., Japan; Dainippon Pharmaceutical Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP2006169155	A	20060629	2004JP-0362562	20041215
PRAI 2004JP-0362562		20041215		
OS CASREACT 145:83396; MARPAT 145:83396				

GI



AB The imides I (A = C2-4 alkylene, C2-4 alkenylene; D = CO, SO2; Y = C1-2 alkylene; Z = (substituted) CH2, (substituted) NH), useful for psychotropic agents for treatment of schizophrenia, senile psychosis, manic-depressive psychosis, neuropathy, etc. (no data), are prepared by treatment of cyclic amines II (Z = same as above) with Y(CH2X)2 (X = anion-generating group; Y = same as above) in the presence of K2CO3 having sp. surface area <1.8 m2/g, and treatment of the resulting spiro quaternary ammonium salts with imides III (A, D = same as above) in the presence of solid inorg. bases. Thus, (1R,2R)-1,2-bis(methanesulfonyloxymethyl)cyclohexane was treated with 4-(1,2-benzisothiazol-3-yl)piperazine in the presence of K2CO3 (sp. surface area 0.6 m2/g) and Bu4N+HSO4-, and treated with hexahydro(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione in the presence of K2CO3 and H2O to give 2-[[(1R,2R)-2-[[4-(1,2-benzoisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione with yield of carbonic acid-derived byproduct 1.5%.
IT 367514-87-2P, 2-[[(1R,2R)-2-[[4-(1,2-Benzoisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of imides as intermediates for psychotropic agents from cyclic amines via spiro quaternary ammonium salts by using K2CO3 with predetd. sp. surface area)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L18 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:627400 HCAPLUS
DN 145:83395
TI Preparation of imides as intermediates for psychotropic agents
IN Ae, Nobuyuki; Bando, Hisashi
PA Sumitomo Chemical Co., Ltd., Japan; Dainippon Pharmaceutical Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP2006169154	A	20060629	2004JP-0362561	20041215
PRAI 2004JP-0362561		20041215		

OS MARPAT 145:83395
GI



AB The imides I [A = C2-4 alkylene, C2-4 alkenylene; D = CO, SO2; Y = C1-2 alkylene; Z = (substituted) CH2, (substituted) NH], useful for psychotropic agents for treatment of schizophrenia, senile psychosis, manic-depressive psychosis, neuropathy, etc. (no data), are prepared by treatment of cyclic amines II (Z = same as above) with Y(CH2X)2 (X = anion-generating group; Y = same as above) in the presence of K2CO3 having average particle size (50%D) ≤200 μm, and treatment of the resulting spiro quaternary ammonium salts with imides III (A, D = same as above) in the presence of solid inorg. bases. Thus, (1R,2R)-1,2-bis(methanesulfonyloxymethyl)cyclohexane was treated with 4-(1,2-benzisothiazol-3-yl)piperazine in the presence of K2CO3 (50%D 11 μm) and Bu4N+HSO4-, and treated with hexahydro(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione in the presence of K2CO3 and H2O to give 2-[[(1R,2R)-2-[[4-(1,2-benzoisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione.
IT 367514-87-2P, 2-[[(1R,2R)-2-[[4-(1,2-Benzoisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of imides as intermediates for psychotropic agents from cyclic amines via spiro quaternary ammonium salts by using K2CO3 with predetd. sp. surface area)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L18 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:962496 HCAPLUS
DN 143:242037
TI Method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia
IN Ishiyama, Takeo
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005080976	A1	20050901	2005WO-JP02838	20050216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP---1726952	A1	20061129	2005EP-0710541	20050216
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US20071606537	A1	20070712	2006US-0589804	20060817
PRAI 2004JP-0044986	A	20040220		
2005WO-JP02838	W	20050216		

AB A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor dysfunction as an animal model of schizophrenia and with the use of reference memory problems, wherein there has been found concrete means for detecting any difference in activity between typical antipsychotic drug and atypical antipsychotic drug. There is provided an in vivo animal model for screening of an ameliorating agent for cognitive dysfunction by schizophrenia.
IT 367514-87-2, Lurasidone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:99501 HCAPLUS
DN 142:198101
TI Process for producing benzisothiazolylpiperazinylmethylcyclohexylmethylbicycloheptanedicarboxyimide hydrochloride
IN Kakiya, Yuzo; Oda, Mayumi
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005009999	A1	20050203	2004WO-JP11035	20040727
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2004259305	A1	20050203	2004AU-0259305	20040727
CA---2538265	A1	20050203	2004CA-2538265	20040727
EP---1652848	A1	20060503	2004EP-0748182	20040727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN---1832946	A	20060913	CN 2004-80022168	20040727
BR2004013081	A	20061003	2004BR-0013081	20040727
US2006194970	A1	20060831	2006US-0565105	20060119
MX2006PA01128	A	20060907	2006MX-PA01128	20060127
IN2006CN00349	A	20070706	2006IN-CN00349	20060127
PRAI 2003JP-0281860	A	20030729		
2004WO-JP11035	W	20040727		

OS CASREACT 142:198101
GI



I

AB Claimed is a process for producing the title compound I.HCl or enantiomers thereof by treating I or enantiomers thereof with an aqueous hydrochloric acid solution in a hydrophilic solvent and crystallizing I.HCl or enantiomers thereof. I.HCl is a psychotropic agent (no data). Thus, I in acetone was heated under reflux; an aqueous HCl solution was added over 15 min to the solution of I in acetone at 55°C; the resulting solution was stirred at 60°C for 1 h; said solution was cooled to 0°C and stirred at 0°C for 1 h to give I.HCl.
IT 367514-88-3P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(crystallization of benzisothiazolylpiperazinylmethylcyclohexylmethylbicycloheptanedicarboxyimide hydrochloride)
RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-,

L18 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 367514-87-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(crystallization of benzisothiazolylpiperazinylmethylcyclohexylmethylbicycloheptanedicarboxyimide hydrochloride)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:1154706 HCAPLUS
DN 142:69202
TI Therapeutic agent for senile dementia
IN Ohno, Yukihiro; Ishiyama, Takeo
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004113333	A1	20041229	2004WO-JP09095	20040622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2004249621	A1	20041229	2004AU-0249621	20040622
CA---2531980	A1	20041229	2004CA-2531980	20040622
EP---1637530	A1	20060322	2004EP-0746564	20040622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN---1826338	A	20060830	CN 2004-80017534	20040622
US2006142276	A1	20060629	2005US-0562039	20051222
IN2005CN03485	A	20070608	2005IN-CN03485	20051222
PRAI 2003JP-0178386	A	20030623		
2004WO-JP09095	W	20040622		

OS MARPAT 142:69202
AB A therapeutic/preventive agent for cognition dysfunctions contains as an active ingredient an imide derivative (Markush structure given). The bioactivity of the imide derivative of this invention was demonstrated.
IT 139627-39-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(imide derivative as therapeutic agent for senile dementia)
RN 139627-39-7 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:182710 HCAPLUS
DN 140:210810
TI Remedy for integration dysfunction syndrome
IN Nakamura, Mitsutaka; Ogasa, Masaaki; Sami, Shunsuke
PA Sumitomo Pharmaceuticals Company, Limited, Japan
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2004017973	A1	20040304	2003WO-JP10490	20030820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2003257589	A1	20040311	2003AU-0257589	20030820
EP---1535616	A1	20050601	2003EP-0792731	20030820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US2006025422	A1	20060202	2005US-0525021	20050218
PRAI 2002US-404927P	P	20020822		
2003WO-JP10490	W	20030820		

AB It is intended to provide a novel method of treating integration dysfunction syndrome. Namely, 5 mg to 120 mg/day of an active compound (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptane dicarboxyimide or its pharmaceutically acceptable salt (for example, hydrochloride) is orally administered to a patient with integration dysfunction syndrome once a day. According to this method, broad symptoms of integration dysfunction syndrome, in particular, pos. symptoms and neg. symptoms, can be ameliorated without causing any extrapyramidal reactions.
IT 367514-88-3
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(remedy for integration dysfunction syndrome)
RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L18 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:424505 HCAPLUS
DN 139:6890
TI Preparation of imides as intermediates for psychotropic agents
IN Kiyoshima, Yujiro; Bando, Hisashi
PA Sumitomo Chemical Co., Ltd., Japan; Sumitomo Pharmaceuticals Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP2003160583	A	20030603	2001JP-0360426	20011127
PRAI 2001JP-0360426		20011127		

OS MARPAT 139:6890
GI



I

II



III

AB Imides I [A = (un)substituted C2-4 alkylene, (un)substituted C2-4 alkenylene; D = CO, SO2; Y = (un)substituted C1-2 alkylene; Z = (un)substituted CH2, (un)substituted NH], useful for psychotropic agents for treatment of schizophrenia, manic-depressive psychosis, neuropathy, etc., are prepared by treatment of imides II (A, D = same as above) with quaternary ammonium salts III (Y, Z = same as above; X- = anion) in the presence of solid inorg. bases and H2O in aromatic hydrocarbon solvents. Thus, MePh solution of 4'-(1,2-benzisothiazol-3-yl)-(3aR,7aR)-octahydro-spiro[2H-isoindole-2,1'-piperazinium] methanesulfonate was refluxed with hexahydro-(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione, K2CO3, and H2O for 2 h to give 83% 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione.
IT 367514-87-2P 535933-87-0P, N-[[2-[[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of imides as intermediates for psychotropic agents in presence of solid inorg. bases and water)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 535933-87-0 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro- (CA INDEX NAME)



L18 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:240535 HCAPLUS
DN 136:268164
TI Oral compositions with favorable disintegration characteristics
IN Fujihara, Kazuyuki
PA Sumitomo Pharmaceuticals Company, Limited, Japan
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002024166	A1	20020328	2001WO-JP07983	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU-200186237	A	20020402	2001AU-0086237	20010914
CA---2424001	A1	20030320	2001CA-2424001	20010914
EP---1327440	A1	20030716	2001EP-0965637	20010914
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, MK, CY, AL, TR				
US2004028741	A1	20040212	2003US-0381036	20030321
PRAI 2000JP-0282234	A	20000922		
2001WO-JP07983	W	20010914		

AB Disclosed are oral compns. containing a hardly water-soluble active ingredient and having favorable disintegration characteristics which comprise a molded solid article (for example, granules) obtained by mixing the hardly water-soluble active ingredient, a first disintegrating agent and a water-soluble filler with the use of a water-soluble polymer binder and then mixing this molded solid article with a second disintegrating agent, or a molded solid article obtained by mixing the hardly water-soluble active ingredient, a disintegrating agent and a sugar alc. with the use of a water-soluble polymer binder. When orally administered, these prepns. show excellent elution of the active ingredient in the digestive tract. Moreover, these prepns. can show the same elution behavior at different contents of the active ingredient and thus enable the selection of the most suitable drug for each patient, which makes these prepns. highly useful in clin. medicine. A film-coated tablet was prepared form granules containing N-[4-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2.2.1]heptanedicarboxy imide hydrochloride 10, lactose 50, sodium croscarmellose 6 mg, and polyvinyl alc. 1.2 mg, calcium hydrogen phosphate anhydride 35, crystalline cellulose 17, and magnesium stearate 0.8 mg, and a coating material containing hydroxypropyl Me cellulose 1.95, titanium oxide 0.6, concentrate glycerin 0.45 mg, and carnauba wax q.s.
IT 367514-88-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients)
RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:762782 HCAPLUS
DN 135:322722
TI Coating agents for sustained-release oral preparations containing basic drugs
IN Nishii, Hiroyuki; Kobayashi, Hirohisa; Otoda, Kazuya
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2001076557	A1	20011018	2001WO-JP03024	20010409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI 2000JP-0107671	A	20000410		

AB Disclosed are pH-independent sustained release prepns. capable of releasing a drug independently from the pH value in the gastric tract. These sustained release prepns. are characterized in that a drug-containing core is coated with (1) a first layer made of a water-insol. polymer, and (2) a second layer made of an enteric polymer and a water-soluble polymer. Core granules were prepared containing perospirone·HCl, crystalline cellulose, PVP, starch and silica. The granules were coated with a first composition containing Et cellulose, talc, tri-Et citrate, ethanol, and water, and then a second composition containing methacrylate copolymer, PVP, sucrose ester, Macrogol 6000, and water.
IT 367514-87-2 367514-88-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymeric coating agents for sustained-release oral prepns. containing basic drugs)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:462314 HCAPLUS
DN 125:142768
TI Preparation of heterocycle-containing lactam derivatives as psychotropics
IN Kojima, Atsuyuki; Antoku, Fujio; Yoshigi, Mayumi; Tanno, Norihiko; Nishihara, Toshio; Toyoda, Tomohiro; Ohno, Yukihiro
PA Sumitomo Pharmaceuticals Company, Limited, Japan
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO9614297	A1	19960517	1995WO-JP02256	19951106
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP3948744	B2	20070725	1996JP-0515196	19951106
PRAI 1994JP-0295601	A	19941104		
1995WO-JP02256	W	19951106		

OS MARPAT 125:142768
GI



II

AB Lactam derivs. represented by general formula [I; R1, R2, R3, R4 = H or lower alkyl, provided a pair of R1 and R2, R3 and R4, R1 and R3, or R2 and R4 may form a hydrocarbon ring which may be bridged with lower alkylene or oxygen, and the lower alkylene and the hydrocarbon ring may be substituted by at least one alkyl group; n = 0 or 1; A = lower alkylene, lower alkenylene or a hydrocarbon ring which may be bridged with lower alkylene (which may be substituted by at least one alkyl or hydroxy group) or oxygen, and the lower alkylene, the lower alkenylene and the hydrocarbon ring may be each substituted by at least one alkyl or hydroxy group; p, q = 0, 1 or 2; G = N or CH and Ar = heteroaryl or aromatic hydrocarbon group, or alternatively G = CH and Ar = phenoxy, provided the heteroaryl group, the aromatic hydrocarbon group and the phenoxy group may be each substituted by at least one lower alkyl, lower alkoxy or halogeno] or acid-addition salts thereof, which have excellent characteristics as psychotropic drugs, and being useful for treating schizophrenia, senile psychosis, manic depressive psychosis, neurosis, and so forth, are prepared Thus, (1R,2S)-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cyclohexanedicarboximide was reduced by LiAlH4 in THF and then by Et3Si in a mixture of CF3CO2H and CH2Cl2 to give the title compound (II). II in vitro inhibited 80% the binding of dopamine D2 receptor ligand, [3H]raclopride, to rat extrapyramidal membrane and 81% the binding of serotonin 5-HT2 receptor ligand, [3H]ketanserin, to rat whole brain membrane fraction (excluding cerebellum), and showed Ki of 0.73 nM for inhibiting the binding of dopamine D4 receptor ligand, [3H]spiperone, to human D4.4-expressing CHO cell membrane fraction.
IT 139505-45-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocycle-containing lactam derivs. as psychotropics)
RN 139505-45-6 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-

L18 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



L18 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:151794 HCAPLUS
DN 116:151794
TI Preparation of [[[(carboximidomethyl)cycloalkyl]methyl]azinyl]arenes as antipsychotics
IN Saji, Ikutaro; Muto, Masayuki; Tanno, Norihiko; Yoshigi, Mayumi
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO Eur. Pat. Appl., 67 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP----464846	A1	19920108	1991EP-0111223	19910705
EP----464846	B1	19980422		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP--05017440	A	19930126	1991JP-0183640	19910627
JP---2800953	B2	19980921		
CA---2046429	A1	19920107	1991CA-2046429	19910705
CA---2046429	C	20030916		
AT----165359	T	19980515	1991AT-0111223	19910705
ES---2115599	T3	19980701	1991ES-0111223	19910705
US---5532372	A	19960702	1993US-0113320	19930830
US---5780632	A	19980714	1996US-0634738	19960418
PRAI 1990JP-0180271	A	19900706		
1991US-0726172	B1	19910705		
1993US-0113320	A3	19930830		

OS CASREACT 116:151794; MARPAT 116:151794
GI



I



II



III

AB Title compds. [I; R1-R4 = H, alkyl; R1R2 = nonarom. hydrocarbylene; R1R3 = (aromatic) (substituted) (bridged) hydrocarbylene; X = CO, SO2; n = 0, 1; A = (substituted) (bridged) nonarom. hydrocarbon ring; p, q = 0-2; X1 = (hetero)aryl, PhCO, PhO, PhS, and G = N, CH, COH; or X1 = biphenylmethylidene, G = C] were prepared Thus, spiro derivative II (preparation from trans-1,2-cyclohexanecarboxylic anhydride given) was refluxed with bicyclo[2.2.1]heptane-2-exo-3-exo-dicarboximide, K2CO3, and dibenzo-18-crown-6 in PhMe to give title compound III. III showed ED50 of 10.3 mg/kg orally for suppression of apomorphine-induced climbing behavior in mice.
IT 139505-45-6P 139563-18-1P 139563-20-5P
139563-21-6P 139563-24-9P 139563-25-0P

L18 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
139563-29-4P 139627-39-7P 139627-40-0P
194861-74-0P 194861-82-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antipsychotic)
RN 139505-45-6 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 139563-18-1 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, monohydrochloride, [2(trans),3aα,4β,7β,7aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 139563-20-5 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, [2(trans),3aα,4β,7β,7aα]-(+)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139563-19-2
CMF C28 H36 N4 O2 S

Rotation (+). Absolute stereochemistry unknown.

L18 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 139563-21-6 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, monohydrochloride, [2(trans),3aα,4β,7β,7aα]-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



● HCl

RN 139563-24-9 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, monohydrochloride, [2(1R*,2R*),3aα,4α,7a,7aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L18 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 139563-25-0 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, monohydrochloride, [2(1R*,2S*),3aα,4β,7β,7aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 139563-29-4 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, monohydrochloride, [2(trans),3aα,4β,7β,7aα]-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L18 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 139627-39-7 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 139627-40-0 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(2R,3R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)-rel-(-)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139627-39-7
CMF C28 H36 N4 O2 S

Rotation (-). Absolute stereochemistry unknown.

L18 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



RN 194861-74-0 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, [2(1R*,2R*),3aα,4α,7α,7aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 194861-82-0 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, [2(1R*,2S*),3aα,4β,7β,7aα]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L18 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



=> d bib abs hitstr l19 tot

L19 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1363699 HCAPLUS
DN 148:24465
TI Melatonin agonist and antipsychotic agent combinations for treatment of insomnia
IN Polymeropoulos, Mihael H.; Wolfgang, Curt D.; Birznieks, Gunther; Phadke, Deepak
PA Vanda Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 20pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2007137224	A2	20071129	2007WO-US69366	20070521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI 2006US-747866P	P	20060522		

AB Disclosed are combinations and combination therapies for the treatment of insomnia in patients with psychotic disorders or with psychotic features, patients with bipolar depression, and patients with major depression with psychotic features.
IT 367514-88-3, SM-13496 367514-88-3D, SM-13496, metabolites
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melatonin agonist and antipsychotic agent combinations for treatment of insomnia)
RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-,

L19 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L19 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1277443 HCAPLUS
DN 147:515074
TI Escitalopram for improving diminished cognition processes
IN Svensson, Hans Torgny
PA H. Lundbeck A/S, Den.
SO PCT Int. Appl., 24pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2007124757	A2	20071108	2007WO-DK50050	20070430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI 2006DK-0000621	A	20060502		

AB The invention relates to the use of the compound escitalopram (INN-name), i.e. (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
IT 367514-87-2, Lurasidone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(escitalopram for improving diminished cognitive processes)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1270852 HCAPLUS
DN 147:496359
TI Use of escitalopram for improvement of cognition in a condition where the cognitive processes are diminished
IN Svensson, Hans Torgny
PA H. Lundbeck A/S, Den.
SO U.S. Pat. Appl. Publ., 11pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US2007259952	A1	20071108	2007US-0741371	20070427
PRAI 2006US-746238P	P	20060502		

AB The invention discloses the use of the compound escitalopram (INN-name), i.e. (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
IT 367514-87-2, Lurasidone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(escitalopram for improvement of cognition in condition with diminished cognitive processes)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:950847 HCAPLUS
DN 145:342440
TI Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
IN Pyke, Robert; Ceci, Angelo
PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co KG
SO PCT Int. Appl., 30pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2006096439	A2	20060914	2006WO-US07379	20060227
WO2006096439	A3	20070208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA---2599699	A1	20060914	2006CA-2599699	20060228
US2006204486	A1	20060914	2006US-0364306	20060228
EP---1858517	A2	20071128	2006EP-0736660	20060228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI 2005US-658566P	P	20050304		
2006WO-US07379	W	20060227		

AB The invention relates to new pharmaceutical compns. for the treatment and/or prevention of schizophrenia and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one addnl. active ingredient for the treatment and/or prevention of schizophrenia and methods for the preparation thereof.
IT 367514-87-2, Lurasidone 367514-88-3, SM 13496
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(flibanserin compns. for the treatment and/or prevention of schizophrenia and related diseases)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L19 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:918625 HCAPLUS
DN 145:315008
TI Preparation of spiro[cyclohexane-1,4'-quinazoline] derivatives for use as PDE7 inhibitors for the treatment of neuropathic pain
IN Cox, Peter; Kinloch, Ross Anderson; Maw, Graham Nigel
PA Pfizer Limited, UK
SO PCT Int. Appl., 108pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2006092691	A1	20060908	2006WO-IB00369	20060216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU2006219643	A1	20060908	2006AU-0219643	20060216
CA---2599662	A1	20060908	2006CA-2599662	20060216
EP---1855686	A1	20071121	2006EP-0710434	20060216
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP2006241159	A	20060914	2006JP-0053415	20060228
KR2007107099	A	20071106	2007KR-0720010	20070831
IN2007DN07221	A	20071012	2007IN-DN07221	20070919
PRAI 2005GB-0004209	A	20050301		
2005US-675761P	P	20050427		
2006WO-IB00369	W	20060216		

OS MARPAT 145:315008
GI





AB Compds. I-III [Ring B = (un)substituted six-membered aryl or heteroaryl ring; Ring A = (un)substituted spirocycle or spiroheterocycle; X = O or NH, NNH2, etc.; Y = O, S, NH, etc.; Z = CHNO2, O, S, etc.; Z1 = H, Me, NH2, etc.] are disclosed as phosphodiesterase 7 (PDE7) inhibitors for use in the manuf. of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an inhibitor of PDE7. Methods for prepg. title compds. are given. Thus, e.g., IV was prepd. by substitution of trans-3-[(benzyloxy)methyl]cyclobutyl p-toluenesulfonate (prepn. given) with 8'-chloro-5'-hydroxy-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one followed by deprotection and oxidn. In PDE7A inhibition assays, IV demonstrated a Ki value of 1.9 (nM).

L19 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 367514-87-2, Lurasidone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase 7 inhibiting compds. useful in treatment of neuropathic pain)
RN 367514-87-2 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:474939 HCAPLUS
DN 143:1317
TI Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
IN Buntinx, Erik
PA Belg.
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2005119253	A1	20050602	2003US-0725965	20031202
	US2005119248	A1	20050602	2004US-0752423	20040106
	US2005119249	A1	20050602	2004US-0803793	20040318
	US2005203130	A1	20050915	2004US-0984683	20041109
	CA---2547639	A1	20050616	2004CA-2547639	20041202
	WO2005053796	A1	20050616	2004WO-BE00172	20041202
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP---1708790	A1	20061011	2004EP-0801138	20041202
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	JP2007513095	T	20070524	2006JP-0541759	20041202
	US2007078162	A1	20070405	2006US-0580962	20060531
PRAI	2003CA-2451798	A	20031202		
	2003EP-0447279	A	20031202		
	2003US-0725965	A2	20031202		
	2004EP-0447001	A	20040105		
	2004US-0752423	A2	20040106		
	2004CA-2461248	A	20040318		
	2004EP-0447066	A	20040318		
	2004US-0803793	A2	20040318		
	2004EP-0025035	A	20041021		
	2004JP-0349085	A	20041104		
	2004US-0984683	A	20041109		
	2004CA-2487529	A	20041115		
	2004WO-BE00172	W	20041202		

AB The present invention relates to methods of treating the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-...) using compds. and compns. of compds. having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compds. having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compds. having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compns. of said compds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biol. compound or in two different chemical and/or biol. compds. The combination can also be used to augment the therapeutic effect of or to provide a faster onset of the therapeutic effect of a selective serotonin re-uptake inhibitor, a norepinephrine re-uptake inhibitor, or a musculoskeletal disease-treating COX-2 inhibitor. Pharmaceutical compns. are also claimed.
IT 367514-88-3, SM 13496
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L19 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(as neuroleptic agent, augmenting therapeutic effect of; treating underlying dysregulation of emotional functionality of mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists)
RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L19 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:474936 HCAPLUS
DN 143:1315
TI Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
IN Buntinx, Erik
PA Belg.
SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 725,965.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2005119248	A1	20050602	2004US-0752423	20040106
	US2005119253	A1	20050602	2003US-0725965	20031202
	US2005119249	A1	20050602	2004US-0803793	20040318
	US2005203130	A1	20050915	2004US-0984683	20041109
	CA---2547639	A1	20050616	2004CA-2547639	20041202
	WO2005053796	A1	20050616	2004WO-BE00172	20041202
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP---1708790	A1	20061011	2004EP-0801138	20041202
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	JP2007513095	T	20070524	2006JP-0541759	20041202
	US2007078162	A1	20070405	2006US-0580962	20060531
PRAI	2003US-0725965	A2	20031202		
	2003CA-2451798	A	20031202		
	2003EP-0447279	A	20031202		
	2004EP-0447001	A	20040105		
	2004US-0752423	A2	20040106		
	2004CA-2461248	A	20040318		
	2004EP-0447066	A	20040318		
	2004US-0803793	A2	20040318		
	2004EP-0025035	A	20041021		
	2004JP-0349085	A	20041104		
	2004US-0984683	A	20041109		
	2004CA-2487529	A	20041115		
	2004WO-BE00172	W	20041202		

AB The present invention relates to methods of treating of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-...) using compds. and compns. of compds. having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compds. having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compds. having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compns. of said compds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biol. compound or in two different chemical and/or biol. compds. The combination can also be used to augment the therapeutic effect of or to provide a faster onset of the therapeutic effect of a selective serotonin re-uptake inhibitor, a norepinephrine re-uptake inhibitor, an NK1 antagonist, or a musculoskeletal disease-treating COX-2 inhibitor. Pharmaceutical compns. are also claimed.
IT 367514-88-3, SM 13496
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as neuroleptic agent, augmenting therapeutic effect of; treating underlying dysregulation of emotional functionality of mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists)
RN 367514-88-3 HCAPLUS

L19 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L19 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:633455 HCAPLUS
DN 139:159958
TI Valproate compound-atypical antipsychotic agent combination therapy for treatment of schizophrenia
IN Sommerville, Kenneth W.; Gilbert, Adrienne L.; Tracy, Katherine A.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003066039	A1	20030814	2003WO-US02540	20030129
	W: CA, JP, MX				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA---2475839	A1	20030814	2003CA-2475839	20030129
	EP---1480629	A1	20041201	2003EP-0737557	20030129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK				
	JP2006505489	T	20060216	2003JP-0565463	20030129
	MX2004PA07752	A	20050617	2004MX-PA07752	20040809
PRAI	2002US-0071733	A	20020208		
	2003WO-US02540	W	20030129		

AB The invention discloses a treatment for schizophrenia. It has been discovered that schizophrenia will respond to the combination of an atypical antipsychotic, e.g. olanzapine, and a valproate compound, e.g. divalproex sodium. This combination is especially useful for alleviating the acute symptoms of schizophrenia. The invention also extends to new formulations containing an antipsychotic in combination with a valproate compound
IT 367514-88-3, SM-13496
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(valproate compound-atypical antipsychotic agent combination therapy for treatment of schizophrenia)
RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

L19 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:521465 HCAPLUS
DN 137:98994
TI Pharmaceuticals containing a combination of norepinephrine reuptake inhibitors and neuroleptics
IN Wong, Erik Ho Fong; Gallen, Christopher C.; Svensson, Torgny
PA Pharmacia & Upjohn Company, USA; Pharmacia AB
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002053140	A2	20020711	2001WO-US45871	20011227
	WO2002053140	A3	20021024		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2431041	A1	20020711	2001CA-2431041	20011227
	AU2002232470	A1	20020716	2002AU-0232470	20011227
	EP---1352675	A2	20031022	2001EP-0991997	20011227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP2004517112	T	20040610	2002JP-0554091	20011227
	NZ-----526801	A	20050729	2001NZ-0526801	20011227
	US2002156067	A1	20021024	2001US-0035100	20011228
	US---6964962	B2	20051115		
	MX2003PA06003	A	20050908	2003MX-PA06003	20030702
	US2006003992	A1	20060105	2005US-0219901	20050906
PRAI	2001US-259286P	P	20010102		
	2001WO-US45871	W	20011227		
	2001US-0035100	A3	20011228		

AB A composition comprising: (a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a salt; and (b) 1 or more neuroleptics is provided. The composition is useful in treating disorders or diseases of the central nervous system, and particularly useful in treating schizophrenia. A pharmaceutical composition was prepared by combining reboxetine with a neuroleptic in an acceptable carrier. The composition contains 0.01-10 mg rebexetine and 25-300 mg clozapine.
IT 367514-88-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals containing combination of norepinephrine reuptake inhibitors and neuroleptics)
RN 367514-88-3 HCAPLUS
CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

```
=> d his

     (FILE 'HOME' ENTERED AT 10:50:54 ON 09 JAN 2008)

     FILE 'HCAPLUS' ENTERED AT 10:51:04 ON 09 JAN 2008
L1             1 US20060194970/PN

     FILE 'REGISTRY' ENTERED AT 10:51:34 ON 09 JAN 2008

     FILE 'HCAPLUS' ENTERED AT 10:51:34 ON 09 JAN 2008
L2             TRA L1 1- RN :        8 TERMS

     FILE 'REGISTRY' ENTERED AT 10:51:34 ON 09 JAN 2008
L3             8 SEA L2
L4           218 C28H36N4O2S
L5            17 L4 AND NSC3-C6/ES
L6             2 L4 AND L3
L7            15 NC4-C5-C5/ES AND L5

     FILE 'HCAPLUS' ENTERED AT 10:54:25 ON 09 JAN 2008
L8            23 L7
L9             9 LURASIDON#
L10            8 LURASIDON# (1A) HYDROCHLORID? OR SM 13496 OR SM13496
L11            5 L8-10 (L) PREP+NT/RL
L12           24 L8-11
                 E KAKIYA Y/AU
L13            6 E3,E6-7
                 E KAKIYA N/AU
                 E ODA M/AU
L14          287 E3-4
                 E ODA MAYUMI/AU
L15           24 E3-4
                 E ODA N/AU
L16           23 E18
                 E YUZO K/AU
                 E YUZO N/AU
                 E MAYUMI O/AU
                 E MAYUMI N/AU
L17      142046 (DAINIPPON OR SUMITOMO OR DAI (1A) NIPPON)/PA,CS
L18           15 L12 AND L13-17
L19            9 L12 NOT L18

     FILE 'HCAOLD' ENTERED AT 11:36:32 ON 09 JAN 2008
L20            0 L7

=>
```